4 Reasons Clinical Trials Don't Work: Marty Tenenbaum, Cancer Commons


Marty Tenenbaum, Founder, Cancer Commons

Bio and Contact Info

Listen (4:28) Why Cancer Commons?

Listen (6:07) Four reasons why clinical trials don't work

Listen (6:57) How do we go about changing the system?

Listen (4:35) What do you mean by Rapid Learning Community?

Listen (4:48) What obstacles do Cancer Commons partners face in sharing more data?

Listen (1:24) The difference between a cancer researcher and a patient is a diagnosis

"At the end of the day, we're all patients," says Marty Tenenbaum, Founder of Cancer Commons, in today's interview.

Marty is a tough cookie. He's a survivor of metastatic melanoma--not a fun one--and he's been getting traction around the biomedical research industry.

Here's the thing. Marty's survival was really by chance.

Cancer has been called the "great equalizer," and Marty is fond of saying that "the only difference between a cancer researcher and a cancer patient is a diagnosis." He is on a mission to work with researchers, doctors, policy experts, and patients to improve the system so that success is not just an accident.

But how does one who is not a researcher or leader in the industry go about that? Marty sees the best opportunity in changing the way clinical trials work. In today's interview, he lays out four reasons why the current system fails patients. And he offers his ideas to fix it.

This is where Cancer Commons comes in. Already a successful web entrepreneur, Marty is attempting to break down the walls between trials and patient care with a new "clearing house" for cancer patients. Ideally, he sees a system that would allow for a "trial of one"--where a patient in treatment has access to an experimental therapy. The goal would be to focus on the patient's own recovery and not only some future patient. Important also would be that much more of the patient's data would be available to expedite research and medical therapy.

A good deal of the funding for Cancer Commons has come from Marty's own pockets. He did well as an entrepreneur. And then he survived a tough cancer. He's now devoting all his resources to creating a new paradigm that puts the patient not at the end, but at the beginning of the process,so that many more patients will have the chance he did.

Podcast brought to you by: BioConference Live's "Cancer: Research, Discovery and Therapeutics" - taking place online Oct 16-17, 2013. Register for free now.